vs
CareDx, Inc.（CDNA）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是CareDx, Inc.的1.3倍（$151.1M vs $117.7M），CareDx, Inc.同比增速更快（39.0% vs 3.6%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $514.0K），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs 5.1%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
CDNA vs RGR — 直观对比
营收规模更大
RGR
是对方的1.3倍
$117.7M
营收增速更快
CDNA
高出35.4%
3.6%
自由现金流更多
RGR
多$11.8M
$514.0K
两年增速更快
CDNA
近两年复合增速
5.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $151.1M |
| 净利润 | $2.8M | — |
| 毛利率 | — | 17.8% |
| 营业利润率 | 1.0% | 2.3% |
| 净利率 | 2.4% | — |
| 营收同比 | 39.0% | 3.6% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.05 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARGR
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $151.1M | ||
| Q3 25 | $100.1M | $126.8M | ||
| Q2 25 | $86.7M | $132.5M | ||
| Q1 25 | $84.7M | $135.7M | ||
| Q4 24 | $86.6M | $145.8M | ||
| Q3 24 | $82.9M | $122.3M | ||
| Q2 24 | $92.3M | $130.8M |
净利润CDNARGR
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $1.7M | $1.6M | ||
| Q2 25 | $-8.6M | $-17.2M | ||
| Q1 25 | $-10.4M | $7.8M | ||
| Q4 24 | $87.7M | — | ||
| Q3 24 | $-10.6M | $4.7M | ||
| Q2 24 | $-4.6M | $8.3M |
毛利率CDNARGR
| Q1 26 | — | — | ||
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% |
营业利润率CDNARGR
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 2.3% | ||
| Q3 25 | -0.2% | -2.7% | ||
| Q2 25 | -12.8% | -15.6% | ||
| Q1 25 | -15.8% | 6.2% | ||
| Q4 24 | 97.5% | 7.8% | ||
| Q3 24 | -16.6% | 3.1% | ||
| Q2 24 | -7.9% | 6.9% |
净利率CDNARGR
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | — | ||
| Q3 25 | 1.7% | 1.2% | ||
| Q2 25 | -9.9% | -13.0% | ||
| Q1 25 | -12.2% | 5.7% | ||
| Q4 24 | 101.3% | — | ||
| Q3 24 | -12.8% | 3.9% | ||
| Q2 24 | -5.0% | 6.3% |
每股收益（稀释后）CDNARGR
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $0.22 | ||
| Q3 25 | $0.03 | $0.10 | ||
| Q2 25 | $-0.16 | $-1.05 | ||
| Q1 25 | $-0.19 | $0.46 | ||
| Q4 24 | $1.60 | $0.62 | ||
| Q3 24 | $-0.20 | $0.28 | ||
| Q2 24 | $-0.09 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $283.8M |
| 总资产 | $411.1M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNARGR
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $92.5M | ||
| Q3 25 | $194.2M | $80.8M | ||
| Q2 25 | $186.3M | $101.4M | ||
| Q1 25 | $230.9M | $108.3M | ||
| Q4 24 | $260.7M | $105.5M | ||
| Q3 24 | $240.9M | $96.0M | ||
| Q2 24 | $228.9M | $105.6M |
总债务CDNARGR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNARGR
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $283.8M | ||
| Q3 25 | $311.1M | $279.6M | ||
| Q2 25 | $327.4M | $289.3M | ||
| Q1 25 | $379.3M | $321.5M | ||
| Q4 24 | $378.4M | $319.6M | ||
| Q3 24 | $273.2M | $314.9M | ||
| Q2 24 | $264.7M | $321.5M |
总资产CDNARGR
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $342.0M | ||
| Q3 25 | $432.3M | $342.3M | ||
| Q2 25 | $444.3M | $349.5M | ||
| Q1 25 | $489.6M | $379.0M | ||
| Q4 24 | $491.1M | $384.0M | ||
| Q3 24 | $477.0M | $373.5M | ||
| Q2 24 | $466.8M | $376.7M |
负债/权益比CDNARGR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $12.3M |
| 自由现金流率自由现金流/营收 | 0.4% | 8.2% |
| 资本支出强度资本支出/营收 | — | 2.1% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $38.5M |
8季度趋势，按日历期对齐
经营现金流CDNARGR
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $15.5M | ||
| Q3 25 | $37.4M | $12.9M | ||
| Q2 25 | $9.9M | $14.7M | ||
| Q1 25 | $-26.6M | $11.1M | ||
| Q4 24 | $21.9M | $20.0M | ||
| Q3 24 | $12.5M | $9.4M | ||
| Q2 24 | $18.9M | $18.7M |
自由现金流CDNARGR
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $12.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $10.1M |
自由现金流率CDNARGR
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 7.7% |
资本支出强度CDNARGR
| Q1 26 | — | — | ||
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 5.5% | ||
| Q2 24 | — | 6.6% |
现金转化率CDNARGR
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
